Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | GABRA1 | P14867 | 2/20 | 0.44 |
| ▸ | GABRB2 | P47870 | 2/20 | 0.44 |
| ▸ | ICMT | O60725 | 1/20 | 0.43 |
| ▸ | CA2 | P00918 | 1/20 | 0.40 |
| ▸ | AKR1B1 | P15121 | 1/20 | 0.40 |
| ▸ | GAA | P10253 | 2/20 | 0.40 |
| ▸ | GRIN2D | O15399 | 1/20 | 0.40 |
| ▸ | GRIN3B | O60391 | 1/20 | 0.40 |
| ▸ | GRIN1 | Q05586 | 1/20 | 0.40 |
| ▸ | GRIN2A | Q12879 | 1/20 | 0.40 |
| ▸ | GRIN2B | Q13224 | 1/20 | 0.40 |
| ▸ | GRIN2C | Q14957 | 1/20 | 0.40 |
| ▸ | GRIN3A | Q8TCU5 | 1/20 | 0.40 |
| ▸ | SIGMAR1 | Q99720 | 1/20 | 0.40 |
| ▸ | NPSR1 | Q6W5P4 | 1/20 | 0.40 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.39 |
| ▸ | LMNA | P02545 | 1/20 | 0.39 |
| ▸ | POLB | P06746 | 1/20 | 0.39 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.39 |
| ▸ | FGFR1 | P11362 | 1/20 | 0.39 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL10339218 | 0.91 | AKR1B1 (0.46) | ICMTCA2AKR1B1GAANPSR1 | |
| Benzene SCHEMBL15265833 | 0.88 | AKR1B1 (0.50) | CA2AKR1B1GAANPSR1LMNA | |
| SCHEMBL7705057 | 0.85 | ICMT (0.43) | ICMTGAANPSR1 | |
| SCHEMBL27734152 | 0.84 | L3MBTL1 (0.53) | ICMTCA2AKR1B1GAANPSR1 | |
| Acetamide SCHEMBL27416699 | 0.83 | GABRA1 (0.50) | GABRA1GABRB2AKR1B1GAAGRIN2D | |
| Ethane SCHEMBL28047378 | 0.83 | KDM4E (0.41) | ICMTCA2AKR1B1GAANPSR1 | |
| SCHEMBL7704572 | 0.82 | ICMT (0.48) | ICMTALDH1A1 | |
| SCHEMBL3051422 | 0.82 | KDM4E (0.43) | ICMTCA2AKR1B1GAANPSR1 | |
| SCHEMBL1765008 | 0.82 | ALDH1A1 (0.42) | ICMTCA2AKR1B1GAANPSR1 | |
| SCHEMBL24977628 | 0.82 | GABRA1 (0.44) | GABRA1GABRB2AKR1B1POLBALDH1A1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 35 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-106518828-B | Amides myricetin derivative, preparation method and application | 贵州大学 | 2018-10-23 | — | — | CN | claimed |
| CN-106518828-A | Amides myricetin derivative and preparation method and application thereof | 贵州大学 | 2017-03-22 | — | — | CN | claimed |
| CN-1088992-C | Topically administrable compositions containing 3-benzoylphenylacetic acid derivatives for treatment of ophthalmic inflammatory disorders | ALCON LAB INC (US) | 2002-08-14 | — | — | CN | claimed |
| CN-1129397-A | Topically administrable compositions containing 3-benzoylphenylacetic acid derivatives for treatment of ophthalmic inflammatory disorders | ALCON LAB INC (US) | 1996-08-21 | — | — | CN | claimed |
| JP-8245376-A | — | — | None | — | — | JP | disclosed |
| EP-4598916-A1 | HETEROCYCLIC INHIBITORS OF KRAS G12C MUTANT PROTEINS AND USES THEREOF | Amgen Inc. (US) | 2025-08-13 | — | — | EP | disclosed |
| WO-2024076672-A1 | HETEROCYCLIC INHIBITORS OF KRAS G12C MUTANT PROTEINS AND USES THEREOF | AMGEN INC. (US) | 2024-04-11 | — | — | WO | disclosed |
| US-20230159510-A1 | NOVEL PRMT5 INHIBITORS | AMGEN INC. (US) | 2023-05-25 | — | — | US | disclosed |
| US-10927125-B2 | Substituted cinnolines as inhibitors of KRAS G12C | ARAXES PHARMA LLC (US) | 2021-02-23 | — | — | US | disclosed |
| US-20200102321-A1 | SUBSTITUTED QUINAZOLINES AS INHIBITORS OF KRAS G12C | ARAXES PHARMA LLC | 2020-04-02 | — | — | US | disclosed |
| US-10370386-B2 | Substituted quinolines as inhibitors of KRAS G12C | ARAXES PHARMA LLC (US) | 2019-08-06 | — | — | US | disclosed |
| CN-106518828-B | Amides myricetin derivative, preparation method and application | 贵州大学 | 2018-10-23 | — | — | CN | disclosed |
| EP-0921800-A4 | SUBSTITUTED BIPHENYL ISOXAZOLE SULFONAMIDES | BRISTOL MYERS SQUIBB CO (US) | 2000-12-06 | — | — | EP | disclosed |
| EP-0946495-A4 | PHENYL ACETAMIDES AS SPLA2 INHIBITORS | LILLY CO ELI (US) | 2000-04-12 | — | — | EP | disclosed |
| EP-0946495-A1 | PHENYL ACETAMIDES AS SPLA2 INHIBITORS | ELI LILLY AND COMPANY (US) | 1999-10-06 | — | — | EP | disclosed |
| EP-0921800-A1 | SUBSTITUTED BIPHENYL ISOXAZOLE SULFONAMIDES | BRISTOL-MYERS SQUIBB COMPANY (US) | 1999-06-16 | — | — | EP | disclosed |
| WO-1998024756-A1 | PHENYL ACETAMIDES AS SPLA2 INHIBITORS | ELI LILLY AND COMPANY (US) | 1998-06-11 | — | — | WO | disclosed |
| WO-1997029748-A1 | SUBSTITUTED BIPHENYL ISOXAZOLE SULFONAMIDES | BRISTOL-MYERS SQUIBB COMPANY (US) | 1997-08-21 | — | — | WO | disclosed |
| JP-H08245376-A | NEW DIFFERENTIATION-INDUCING ADJUVANT USED FOR CANCER DIFFERENTIAL THERAPY AND CANCER CHEMICAL PROPHYLAXIS | KAKU SEIJO | 1996-09-24 | — | — | JP | disclosed |
| CN-1129397-A | Topically administrable compositions containing 3-benzoylphenylacetic acid derivatives for treatment of ophthalmic inflammatory disorders | ALCON LAB INC (US) | 1996-08-21 | — | — | CN | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-10927125-B2 | Substituted cinnolines as inhibitors of KRAS G12C | KRAS, NRAS, HRAS | GABRA1 4467/4885GABRB2 4301/4885ICMT 2957/4885 |
| US-20200102321-A1 | SUBSTITUTED QUINAZOLINES AS INHIBITORS OF KRAS G12C | KRAS, NRAS, HRAS | GABRA1 4063/4885GABRB2 4296/4885ICMT 2721/4885 |
| US-20230159510-A1 | NOVEL PRMT5 INHIBITORS | PRMT5, PRMT1, PRMT3 | GABRA1 3738/4885GABRB2 3895/4885ICMT 2511/4885 |
| US-10370386-B2 | Substituted quinolines as inhibitors of KRAS G12C | KRAS, NRAS, HRAS | GABRA1 4228/4885GABRB2 4164/4885ICMT 2319/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.